*ST Sailong Co., Ltd.

Announcement on the Progress of Continued Public Transfer of Wholly-Owned Subsidiary Equity

Announcement on the Resignation of the Company's Independent Director

Announcement on Receiving the Advance Notice of Termination of Listing

Response from Yongxin Ruihe (Shenzhen) Accounting Firm (Special General Partnership) regarding the inquiry letter from Sailong Pharmaceutical Group Co., Ltd.

Announcement on the response to the inquiry letter from the Shenzhen Stock Exchange

2025 Annual Report of Independent Director (Zhang Kai)

2025 Annual Report of Independent Director (Zhang Jianmin)

2025 Annual Report of Independent Director (Wang Shufang)

2025 Annual Internal Control Audit Report

Self-evaluation Report on Internal Control for the Year 2025 by Sailong Pharmaceutical Group Co., Ltd.

2025 Annual Board Work Report

2025 Annual Financial Settlement Report

Announcement on Uncovered Losses Exceeding One-third of Paid-in Capital

Explanation from the Audit Committee of the Board of Directors on the Reasonableness of the Company's Provision for Impairment

Announcement on the Provision for Asset Impairment for the Year 2025

Notice of the 2025 Annual Shareholders' Meeting

Announcement of the Twenty-fifth Meeting Resolution of the Fourth Board of Directors

Announcement on the Objections of Some Directors Regarding Regular Reports and Other Matters

Special Explanation on the Intention Not to Distribute Profits for the Year 2025

2026 First Quarter Report

Special Explanation from the Accounting Firm on the Inability to Express an Opinion on the 2025 Financial Report

Special Explanation from the Audit Committee on Matters Involved in Non-standard Audit Opinions

Special Explanation on Matters Involved in the Non-standard Opinion Audit Report and Internal Control Audit Report for 2025

Special Verification Opinion on Special Deductions for Operating Income in 2025 and the Amount of Operating Income After Deductions

Report on the Evaluation of the Accounting Firm's Performance in 2025 and the Audit Committee's Fulfillment of Supervisory Responsibilities

Special Explanation on Non-operating Fund Occupation and Other Related Fund Transactions by the Accounting Firm

Summary Table of Fund Transactions

Special Opinion of the Board of Directors of Sailong Pharmaceutical Group Co., Ltd. on the Independence Self-examination of Independent Directors

2025 Annual Audit Report

2025 Annual Report